GlassScriptPhysician profile
David P Masiello
NPI 1427277573
$21,058.24
in general payments reported to CMS, 2019-2025
71 companies · $3,521 in 2025
The $3,521 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $1,723 · 2021: $2,712 · 2022: $2,816 · 2023: $3,488 · 2024: $3,838 · 2025: $3,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,830.11 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,675.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,677.55 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $1,237.76 | 2019-2025 | Erleada, Balversa, Akeega |
| Beigene USA, INC. | $1,210.91 | 2022-2025 | Brukinsa |
| Pfizer INC. | $1,090.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $850.58 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $748.58 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $743.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $638.54 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.66 | 2019-2025 | Gilotrif |
| Lilly USA, LLC | $528.53 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Beigene, LTD. | $525.00 | 2021 | |
| Eisai INC. | $495.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $458.26 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
| Celgene Corporation | $453.70 | 2019-2025 | Pomalyst, Reblozyl |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $346.49 | 2021-2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $334.21 | 2022-2025 | Fotivda |
| Incyte Corporation | $323.97 | 2019-2025 | Jakafi |
| Puma Biotechnology, INC. | $303.60 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $272.53 | 2020-2025 | Xpovio |
| Abbvie INC. | $250.20 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $248.09 | 2019-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $235.85 | 2021-2025 | Ultomiris |
| Amgen INC. | $235.67 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $232.55 | 2022-2024 | Trodelvy |
| Beone Medicines USA, INC. | $221.07 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $206.29 | 2019-2025 | Tazverik, Onivyde |
| Genentech USA, INC. | $183.66 | 2019-2025 | Polivy, Phesgo, Tecentriq |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Emd Serono, INC. | $164.77 | 2022-2024 | Bavencio |
| Seagen INC. | $151.82 | 2019-2023 | Adcetris, Tukysa |
| Array Biopharma INC | $146.63 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Genzyme Corporation | $124.67 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $115.75 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Exelixis INC. | $111.39 | 2023-2024 | Cabometyx |
| Taiho Oncology, INC. | $107.44 | 2019-2023 | |
| Sobi, INC | $102.25 | 2024-2025 | |
| Blueprint Medicines Corporation | $99.99 | 2023-2024 | Ayvakit |
| Tesaro, INC. | $91.12 | 2019 | |
| Adc Therapeutics America, INC. | $91.02 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $87.80 | 2024-2025 | Orgovyx |
| Myovant Sciences INC. | $86.56 | 2021-2022 | |
| Pharmaessentia USA Corporation | $84.70 | 2025 | Besremi |
| Dova Pharmaceuticals | $74.08 | 2019-2021 | |
| Astellas Pharma US INC | $70.46 | 2023-2024 | Xtandi, Padcev |
| Kite Pharma, INC. | $64.92 | 2022-2025 | Yescarta |
| Tersera Therapeutics LLC | $64.13 | 2019-2024 | Xermelo |
| Verastem, INC. | $61.42 | 2019-2020 | |
| Secura Bio, INC. | $56.90 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $53.24 | 2024-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $52.77 | 2019-2025 | Libtayo |
| Foundation Medicine, INC. | $51.14 | 2019-2023 | |
| Stemline Therapeutics INC. | $44.79 | 2023-2024 | Orserdu, Elzonris |
| Agios Pharmaceuticals, INC. | $44.69 | 2024-2025 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $40.84 | 2021 | |
| Clovis Oncology, INC. | $39.90 | 2019 | |
| Mirati Therapeutics, INC. | $38.72 | 2023 | Krazati |
| Blue Earth Diagnostics | $26.93 | 2023 | |
| Sirtex Medical INC | $24.59 | 2022 | |
| Geron Corporation | $24.22 | 2025 | Rytelo |
| Morphosys, US INC. | $23.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.49 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.39 | 2019-2021 | |
| Legend Biotech USA INC. | $22.23 | 2024 | |
| Recordati_rare_diseases_inc. | $21.71 | 2024 | Sylvant |
| Caris Mpi, INC. | $21.45 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $21.14 | 2023 | Elahere |
| Tolmar Pharmaceuticals, INC. | $19.66 | 2022 | |
| Shield Therapeutics INC | $18.20 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $15.67 | 2024 | Sancuso |
| Shire North American Group INC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Masiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.